The “Things We Do for No Reason” (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent “black and white” conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Hospitals and health systems worldwide have adopted policies for routine replacement of peripheral intravenous catheters (PIVCs) at prespecified time intervals (range, 48-96 hours). This practice accounts for a large number of PIVC reinsertions and places a significant cost burden on the healthcare infrastructure. The authors of this article examine the evidence that has been used to support this practice.

CASE PRESENTATION

A 67-year-old man with metastatic lung cancer presents to a hospital for pain control and “failure to thrive.” In the emergency department, a left antecubital peripheral intravenous catheter (PIVC) is placed. On admission, a prerenal acute kidney injury is noted. During the patient’s entire hospitalization, normal saline with parenteral hydromorphone is administered. On hospital day 4, the pain is still not adequately controlled, and the intravenous opioid is continued. On morning rounds, an intern notes that the PIVC is functioning well, and there are no signs of irritation. However, the nursing staff reminds the team that the PIVC should be changed because it has been in place for 4 days and is “due for replacement.” The patient does not want to receive another skin puncture for routine venous access. Does the PIVC need to be replaced, per routine?

WHY YOU MIGHT THINK ROUTINE PIVC REPLACEMENT IS HELPFUL

PIVC placement is easily the most common procedure performed in the United States. An estimated 200 million PIVCs are placed each year.¹ Given the number of inpatient hospital stays per year in the United States alone—more than 37 million^1,2—data regarding the care, maintenance, and complications of PIVCs are essential to the healthcare infrastructure. 

The recommendation to routinely replace PIVCs dates to 1981, when the Centers for Disease Control and Prevention³ (CDC) issued a guideline that calls for replacing PIVCs every 24 to 48 hours. Most of the data and studies that established that recommendation originated in the 1970s, when catheters varied in length and material, and precise definitions of complications, such as phlebitis—localized vein inflammation characterized by pain, erythema, tenderness, swelling, and a palpable cord^4,5—were not standardized across trials. Research at the time suggested higher rates of complications from IVCs dwelling longer than 48 to 72 hours. The latest (2011) CDC guidelines^6,7 softened the recommendation but still concluded, “There is no need to replace peripheral catheters more frequently than every 72-96 hours.”

The 2011 recommendation^6,7 is based on findings of a 1983 prospective observational study,⁸ a 1991 randomized controlled trial (RCT),⁹ and a 1998 prospective observational study.² The 1983 and 1991 studies found higher rates of PIVC complications after day 2 of cannulation.^8,9 The 1998 study found no increase in the rate of complications after day 3 of catheterization, and its authors, recommending a reevaluation of the need to routinely replace PIVCs, wrote, “[The] hazard for catheter-related complications, phlebitis, catheter-related infections, and mechanical complications did not increase during prolonged catheterization.”²

Results of RCTs conducted by Barker et al.¹⁰ (2004) and Nishanth et al.¹¹ (2009) supported the claim that routine replacement of PIVCs leads to lower rates of thrombophlebitis. Nishanth et al. also included site pain and cannula dislodgement in their definition of phlebitis. Neither study compared blood stream infection rates, but both found higher rates of phlebitis between day 2.5 and day 3. However, Cochrane reviewers Webster et al.¹² questioned the findings of these 2 trials, given their missing data and possibly biased results and conclusions. In the Barker study, patient numbers (screened, eligible, dropout) were unclear; each patient group was unbalanced; protocol deviations were not reported (possibly a result of incomplete data reporting or inappropriate randomization); and varied definitions of phlebitis were allowed, which may have resulted in more events being included. In the Nishanth study, the 100% phlebitis rate for the clinically indicated replacement group seemed extreme, which suggested confounding by an unknown bias or chance. Last, both samples were small: 47 patients (Barker) and 42 patients (Nishanth). Given all these concerns, the 2 trials were excluded from the Cochrane meta-analysis on the subject.¹²

In the 1980s and early 1990s, routine removal and exchange of PIVCs were supported by limited evidence. Current well-designed trial data cast doubt on the need for such a practice.

WHY YOU SHOULD NOT ROUTINELY REPLACE PIVCs

According to the CDC,^6,7 the issue of routine PIVC replacement remains unresolved: “No recommendation is made regarding replacement of peripheral catheters in adults only when clinically indicated.”

Whereas earlier data showed a higher risk of complications with longer dwelling IVs, the majority of contemporary data has failed to support this conclusion. The recent (2015) Cochrane meta-analysis comparing routine with clinically indicated IVC replacement found “no evidence to support changing catheters every 72-96 hours.”¹² Of the 7 studies that fulfilled the criteria for qualitative analysis, only 5 were included (the studies by Barker et al.¹⁰ and Nishanth et al.¹¹ were excluded). The included studies assessed the endpoints of catheter-related blood stream infection (CRBSI), phlebitis, phlebitis per device-days, mortality, cost, and infiltration. Statistically significant differences were found only for cost (favoring clinically indicated replacement) and infiltration (occurring less with routine replacement). 

The largest and most robust RCT in the meta-analysis¹² was conducted by Rickard et al.¹³ (2012). Their nonblinded, intention-to-treat study of 3283 patients used concealed allocation to randomly assign patients to either clinically indicated or routine PIVC replacement in order to evaluate a primary endpoint, phlebitis. Secondary endpoints were CRBSI, venous port infection, IVC tip colonization, infusion failure, number of IVCs needed per patient, IV therapy duration, cost, and mortality. Need for PIVC replacement was methodically monitored (Table) with extensive nursing education and interrater validation. The study found no difference in the groups’ phlebitis rates; the rate was 7% for both routine and clinically indicated replacement (13.08% and 13.11%, respectively, adjusted for phlebitis per 1000 IVC days). In addition, there was no difference in the secondary outcome measures, except cost and number of catheters used, both of which favored clinically indicated replacement. The most serious complication, CRBSI, occurred at essentially the same rate in the 2 replacement arms: 0.11% (routine) and 0% (clinically indicated). Per-patient cost for the entire course of treatment was A$69.24 in the routine group and A$61.66 in the clinically indicated group; the difference was A$7.58 (P < 0.0001). Mean number of catheters used was 1.9 in the routine group and 1.7 in the clinically indicated group; the difference was 0.21 catheter per patient for the treatment course (P < 0.0001). Overall, the study found no important difference in significant outcomes between the 2 study arms.

The other 4 studies in the meta-analysis¹² duplicated these results, with none finding a higher rate of major adverse events.^14-17 All 4 showed virtually equivalent rates of phlebitis, the primary outcome; 3 also examined the secondary outcome measure of blood stream infection, and results were similar, with identical rates of complications. Only 1 trial identified any bloodstream infections (1 per group).¹⁵ The meta-analysis did find that routine catheter replacement resulted in less catheter infiltration. 

Most of the data on PIVC exchange involves phlebitis and other local complications. A prospective study by Stuart et al.¹⁸ and commentary by Collignon et al.¹⁹ underscore the need for further research targeting blood stream infections (sepsis and severe sepsis in particular) as a primary outcome. Blood stream infections, especially those related to PIVC use, are rare entities overall, with most recent data yielding an estimated rate of 0.5 per 1000 catheter-days.²⁰ Given this epidemiologic finding, researchers trying to acquire meaningful data on PIVC-related blood stream infections and subsequent complications would need to have tens of thousands of patients in routine and clinically indicated replacement arms to sufficiently power their studies.²⁰ As they are infeasible, such trials cannot be found in the scientific literature.

Stuart et al.¹⁸ tried addressing the question. Prospectively examining more than 5 million occupied-bed days and the incidence of bloodstream infections by type of intravascular device over a 5-year period, they found that 137 (23.5%) of 583 healthcare-associated Staphylococcus aureus bacteremia (SAB) cases were attributed to PIVC use. PIVC insertions were performed equally (39.6%) in emergency departments and medical wards. About 45% of PIVCs remained in place 4 days or longer. Stuart et al. noted the “significant issue of PIVC-associated SAB” and favored routine removal of PIVCs within 96 hours (4 days). However, 55% of patients in their PIVC-related SAB group had the device in place less than 4 days. In addition, overall incidence of SAB was low: 0.3 per 10,000 occupied-bed days. Further, their study did not adjust device-specific SAB incidence for frequency of device use. For example, the rate of healthcare-acquired SAB was 19.7% for central venous catheters and 23.5% for PIVCs, despite PIVCs being used significantly more often than central lines. Device-specific adjustments would show a vastly different absolute risk of SAB in relation to individual devices. Nevertheless, the overall benefit of and need for routine PIVC replacement must be questioned. The percentage of PIVC-associated SAB in their study and the need for more research in this area should be noted. Given current information, their study and others in the literature underscore the need for selective use, appropriate maintenance, and timely removal of PIVCs.

Pure clinical outcomes are important, but procedural costs are as well. Clinically indicated replacement helps patients avoid an unpleasant procedure and saves money.²¹ If one third of the 37 million annual inpatient admissions require a PIVC for more than 3 days, then a strategy of “replacement when clinically indicated” could prevent almost 2.5 million unnecessary PIVC insertions each year. Equipment cost savings combined with savings of nearly 1 million staff hours could yield an estimated $400 million in savings over a 5-year period.²² Given current data suggesting no harm from clinically indicated PIVC replacement and clear evidence that routine replacement increases needle sticks and costs, it seems time to end the practice of routine PIVC replacement.

Compared with clinically indicated catheter replacement, routine replacement in the absence of a clinical indication (eg, infiltration, phlebitis, infection) provides no added benefit. Studies have consistently found that rates of phlebitis and SAB are not affected by scheduled replacement, though the largest RCT may not have been powered to show a difference in SAB. The present authors’ recommendations for PIVC care are:

• Scrutinize each patient’s need for PIVCs and remove each PIVC as soon as possible.
• Do not make routine replacement of otherwise well-functioning, well-appearing clinically necessary PIVCs the standard of care.
• Regularly examine PIVC sites for signs and symptoms of infection.
• Remove a PIVC immediately on recognition of any clinical sign of a complication (eg, infiltration, phlebitis, localized infection, blood stream infection) and replace the PIVC only if there is a clinical need.
• If replacing PIVCs on a clinical basis, establish protocols for frequency of evaluation for complications; these protocols might mirror those from prior studies (Table).^10,22
• Replace as soon as possible any PIVC inserted during an urgent or emergent situation in which proper insertion technique could not be guaranteed.
• Conduct real-world observational studies to ensure that the switch to clinically driven replacement is safe and develop standardized definitions of complications.

Given the literature findings and the preceding recommendations, the authors conclude that the patient in the case example does not need routine PIVC replacement. His PIVC may remain in place as long as evaluation for local complications is routinely and methodically performed and the device is removed as soon as it is deemed unnecessary (transition to oral opioid therapy).

The long-standing practice of routinely replacing PIVCs every 72 to 96 hours during a hospital stay does not affect any meaningful clinical outcome. Specifically, data do not show that routine replacement prevents phlebitis or blood stream infections. Furthermore, routine PIVC replacement increases patient discomfort, uses resources unnecessarily, and raises hospital costs. Most of the PIVC research has involved phlebitis and other local complications; more research on PIVC use and bloodstream infections is needed. Given the findings in the current literature, routine PIVC replacement should be considered a Thing We Do For No Reason.

Disclosure

Nothing to report. 

Do you think this is a low-value practice? Is this truly a “Thing We Do for No Reason”? Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other “Things We Do for No Reason” topics by emailing [email protected].

The “Things We Do for No Reason” (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent “black and white” conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Hospitals and health systems worldwide have adopted policies for routine replacement of peripheral intravenous catheters (PIVCs) at prespecified time intervals (range, 48-96 hours). This practice accounts for a large number of PIVC reinsertions and places a significant cost burden on the healthcare infrastructure. The authors of this article examine the evidence that has been used to support this practice.

CASE PRESENTATION

A 67-year-old man with metastatic lung cancer presents to a hospital for pain control and “failure to thrive.” In the emergency department, a left antecubital peripheral intravenous catheter (PIVC) is placed. On admission, a prerenal acute kidney injury is noted. During the patient’s entire hospitalization, normal saline with parenteral hydromorphone is administered. On hospital day 4, the pain is still not adequately controlled, and the intravenous opioid is continued. On morning rounds, an intern notes that the PIVC is functioning well, and there are no signs of irritation. However, the nursing staff reminds the team that the PIVC should be changed because it has been in place for 4 days and is “due for replacement.” The patient does not want to receive another skin puncture for routine venous access. Does the PIVC need to be replaced, per routine?

WHY YOU MIGHT THINK ROUTINE PIVC REPLACEMENT IS HELPFUL

PIVC placement is easily the most common procedure performed in the United States. An estimated 200 million PIVCs are placed each year.¹ Given the number of inpatient hospital stays per year in the United States alone—more than 37 million^1,2—data regarding the care, maintenance, and complications of PIVCs are essential to the healthcare infrastructure. 

The recommendation to routinely replace PIVCs dates to 1981, when the Centers for Disease Control and Prevention³ (CDC) issued a guideline that calls for replacing PIVCs every 24 to 48 hours. Most of the data and studies that established that recommendation originated in the 1970s, when catheters varied in length and material, and precise definitions of complications, such as phlebitis—localized vein inflammation characterized by pain, erythema, tenderness, swelling, and a palpable cord^4,5—were not standardized across trials. Research at the time suggested higher rates of complications from IVCs dwelling longer than 48 to 72 hours. The latest (2011) CDC guidelines^6,7 softened the recommendation but still concluded, “There is no need to replace peripheral catheters more frequently than every 72-96 hours.”

The 2011 recommendation^6,7 is based on findings of a 1983 prospective observational study,⁸ a 1991 randomized controlled trial (RCT),⁹ and a 1998 prospective observational study.² The 1983 and 1991 studies found higher rates of PIVC complications after day 2 of cannulation.^8,9 The 1998 study found no increase in the rate of complications after day 3 of catheterization, and its authors, recommending a reevaluation of the need to routinely replace PIVCs, wrote, “[The] hazard for catheter-related complications, phlebitis, catheter-related infections, and mechanical complications did not increase during prolonged catheterization.”²

Results of RCTs conducted by Barker et al.¹⁰ (2004) and Nishanth et al.¹¹ (2009) supported the claim that routine replacement of PIVCs leads to lower rates of thrombophlebitis. Nishanth et al. also included site pain and cannula dislodgement in their definition of phlebitis. Neither study compared blood stream infection rates, but both found higher rates of phlebitis between day 2.5 and day 3. However, Cochrane reviewers Webster et al.¹² questioned the findings of these 2 trials, given their missing data and possibly biased results and conclusions. In the Barker study, patient numbers (screened, eligible, dropout) were unclear; each patient group was unbalanced; protocol deviations were not reported (possibly a result of incomplete data reporting or inappropriate randomization); and varied definitions of phlebitis were allowed, which may have resulted in more events being included. In the Nishanth study, the 100% phlebitis rate for the clinically indicated replacement group seemed extreme, which suggested confounding by an unknown bias or chance. Last, both samples were small: 47 patients (Barker) and 42 patients (Nishanth). Given all these concerns, the 2 trials were excluded from the Cochrane meta-analysis on the subject.¹²

In the 1980s and early 1990s, routine removal and exchange of PIVCs were supported by limited evidence. Current well-designed trial data cast doubt on the need for such a practice.

WHY YOU SHOULD NOT ROUTINELY REPLACE PIVCs

According to the CDC,^6,7 the issue of routine PIVC replacement remains unresolved: “No recommendation is made regarding replacement of peripheral catheters in adults only when clinically indicated.”

Whereas earlier data showed a higher risk of complications with longer dwelling IVs, the majority of contemporary data has failed to support this conclusion. The recent (2015) Cochrane meta-analysis comparing routine with clinically indicated IVC replacement found “no evidence to support changing catheters every 72-96 hours.”¹² Of the 7 studies that fulfilled the criteria for qualitative analysis, only 5 were included (the studies by Barker et al.¹⁰ and Nishanth et al.¹¹ were excluded). The included studies assessed the endpoints of catheter-related blood stream infection (CRBSI), phlebitis, phlebitis per device-days, mortality, cost, and infiltration. Statistically significant differences were found only for cost (favoring clinically indicated replacement) and infiltration (occurring less with routine replacement). 

The largest and most robust RCT in the meta-analysis¹² was conducted by Rickard et al.¹³ (2012). Their nonblinded, intention-to-treat study of 3283 patients used concealed allocation to randomly assign patients to either clinically indicated or routine PIVC replacement in order to evaluate a primary endpoint, phlebitis. Secondary endpoints were CRBSI, venous port infection, IVC tip colonization, infusion failure, number of IVCs needed per patient, IV therapy duration, cost, and mortality. Need for PIVC replacement was methodically monitored (Table) with extensive nursing education and interrater validation. The study found no difference in the groups’ phlebitis rates; the rate was 7% for both routine and clinically indicated replacement (13.08% and 13.11%, respectively, adjusted for phlebitis per 1000 IVC days). In addition, there was no difference in the secondary outcome measures, except cost and number of catheters used, both of which favored clinically indicated replacement. The most serious complication, CRBSI, occurred at essentially the same rate in the 2 replacement arms: 0.11% (routine) and 0% (clinically indicated). Per-patient cost for the entire course of treatment was A$69.24 in the routine group and A$61.66 in the clinically indicated group; the difference was A$7.58 (P < 0.0001). Mean number of catheters used was 1.9 in the routine group and 1.7 in the clinically indicated group; the difference was 0.21 catheter per patient for the treatment course (P < 0.0001). Overall, the study found no important difference in significant outcomes between the 2 study arms.

The other 4 studies in the meta-analysis¹² duplicated these results, with none finding a higher rate of major adverse events.^14-17 All 4 showed virtually equivalent rates of phlebitis, the primary outcome; 3 also examined the secondary outcome measure of blood stream infection, and results were similar, with identical rates of complications. Only 1 trial identified any bloodstream infections (1 per group).¹⁵ The meta-analysis did find that routine catheter replacement resulted in less catheter infiltration. 

Most of the data on PIVC exchange involves phlebitis and other local complications. A prospective study by Stuart et al.¹⁸ and commentary by Collignon et al.¹⁹ underscore the need for further research targeting blood stream infections (sepsis and severe sepsis in particular) as a primary outcome. Blood stream infections, especially those related to PIVC use, are rare entities overall, with most recent data yielding an estimated rate of 0.5 per 1000 catheter-days.²⁰ Given this epidemiologic finding, researchers trying to acquire meaningful data on PIVC-related blood stream infections and subsequent complications would need to have tens of thousands of patients in routine and clinically indicated replacement arms to sufficiently power their studies.²⁰ As they are infeasible, such trials cannot be found in the scientific literature.

Stuart et al.¹⁸ tried addressing the question. Prospectively examining more than 5 million occupied-bed days and the incidence of bloodstream infections by type of intravascular device over a 5-year period, they found that 137 (23.5%) of 583 healthcare-associated Staphylococcus aureus bacteremia (SAB) cases were attributed to PIVC use. PIVC insertions were performed equally (39.6%) in emergency departments and medical wards. About 45% of PIVCs remained in place 4 days or longer. Stuart et al. noted the “significant issue of PIVC-associated SAB” and favored routine removal of PIVCs within 96 hours (4 days). However, 55% of patients in their PIVC-related SAB group had the device in place less than 4 days. In addition, overall incidence of SAB was low: 0.3 per 10,000 occupied-bed days. Further, their study did not adjust device-specific SAB incidence for frequency of device use. For example, the rate of healthcare-acquired SAB was 19.7% for central venous catheters and 23.5% for PIVCs, despite PIVCs being used significantly more often than central lines. Device-specific adjustments would show a vastly different absolute risk of SAB in relation to individual devices. Nevertheless, the overall benefit of and need for routine PIVC replacement must be questioned. The percentage of PIVC-associated SAB in their study and the need for more research in this area should be noted. Given current information, their study and others in the literature underscore the need for selective use, appropriate maintenance, and timely removal of PIVCs.

Pure clinical outcomes are important, but procedural costs are as well. Clinically indicated replacement helps patients avoid an unpleasant procedure and saves money.²¹ If one third of the 37 million annual inpatient admissions require a PIVC for more than 3 days, then a strategy of “replacement when clinically indicated” could prevent almost 2.5 million unnecessary PIVC insertions each year. Equipment cost savings combined with savings of nearly 1 million staff hours could yield an estimated $400 million in savings over a 5-year period.²² Given current data suggesting no harm from clinically indicated PIVC replacement and clear evidence that routine replacement increases needle sticks and costs, it seems time to end the practice of routine PIVC replacement.

Compared with clinically indicated catheter replacement, routine replacement in the absence of a clinical indication (eg, infiltration, phlebitis, infection) provides no added benefit. Studies have consistently found that rates of phlebitis and SAB are not affected by scheduled replacement, though the largest RCT may not have been powered to show a difference in SAB. The present authors’ recommendations for PIVC care are:

• Scrutinize each patient’s need for PIVCs and remove each PIVC as soon as possible.
• Do not make routine replacement of otherwise well-functioning, well-appearing clinically necessary PIVCs the standard of care.
• Regularly examine PIVC sites for signs and symptoms of infection.
• Remove a PIVC immediately on recognition of any clinical sign of a complication (eg, infiltration, phlebitis, localized infection, blood stream infection) and replace the PIVC only if there is a clinical need.
• If replacing PIVCs on a clinical basis, establish protocols for frequency of evaluation for complications; these protocols might mirror those from prior studies (Table).^10,22
• Replace as soon as possible any PIVC inserted during an urgent or emergent situation in which proper insertion technique could not be guaranteed.
• Conduct real-world observational studies to ensure that the switch to clinically driven replacement is safe and develop standardized definitions of complications.

Given the literature findings and the preceding recommendations, the authors conclude that the patient in the case example does not need routine PIVC replacement. His PIVC may remain in place as long as evaluation for local complications is routinely and methodically performed and the device is removed as soon as it is deemed unnecessary (transition to oral opioid therapy).

The long-standing practice of routinely replacing PIVCs every 72 to 96 hours during a hospital stay does not affect any meaningful clinical outcome. Specifically, data do not show that routine replacement prevents phlebitis or blood stream infections. Furthermore, routine PIVC replacement increases patient discomfort, uses resources unnecessarily, and raises hospital costs. Most of the PIVC research has involved phlebitis and other local complications; more research on PIVC use and bloodstream infections is needed. Given the findings in the current literature, routine PIVC replacement should be considered a Thing We Do For No Reason.

Disclosure

Nothing to report. 

Do you think this is a low-value practice? Is this truly a “Thing We Do for No Reason”? Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other “Things We Do for No Reason” topics by emailing [email protected].

The “Things We Do for No Reason” (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent “black and white” conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Hospitals and health systems worldwide have adopted policies for routine replacement of peripheral intravenous catheters (PIVCs) at prespecified time intervals (range, 48-96 hours). This practice accounts for a large number of PIVC reinsertions and places a significant cost burden on the healthcare infrastructure. The authors of this article examine the evidence that has been used to support this practice.

CASE PRESENTATION

A 67-year-old man with metastatic lung cancer presents to a hospital for pain control and “failure to thrive.” In the emergency department, a left antecubital peripheral intravenous catheter (PIVC) is placed. On admission, a prerenal acute kidney injury is noted. During the patient’s entire hospitalization, normal saline with parenteral hydromorphone is administered. On hospital day 4, the pain is still not adequately controlled, and the intravenous opioid is continued. On morning rounds, an intern notes that the PIVC is functioning well, and there are no signs of irritation. However, the nursing staff reminds the team that the PIVC should be changed because it has been in place for 4 days and is “due for replacement.” The patient does not want to receive another skin puncture for routine venous access. Does the PIVC need to be replaced, per routine?

WHY YOU MIGHT THINK ROUTINE PIVC REPLACEMENT IS HELPFUL

PIVC placement is easily the most common procedure performed in the United States. An estimated 200 million PIVCs are placed each year.¹ Given the number of inpatient hospital stays per year in the United States alone—more than 37 million^1,2—data regarding the care, maintenance, and complications of PIVCs are essential to the healthcare infrastructure. 

The recommendation to routinely replace PIVCs dates to 1981, when the Centers for Disease Control and Prevention³ (CDC) issued a guideline that calls for replacing PIVCs every 24 to 48 hours. Most of the data and studies that established that recommendation originated in the 1970s, when catheters varied in length and material, and precise definitions of complications, such as phlebitis—localized vein inflammation characterized by pain, erythema, tenderness, swelling, and a palpable cord^4,5—were not standardized across trials. Research at the time suggested higher rates of complications from IVCs dwelling longer than 48 to 72 hours. The latest (2011) CDC guidelines^6,7 softened the recommendation but still concluded, “There is no need to replace peripheral catheters more frequently than every 72-96 hours.”

The 2011 recommendation^6,7 is based on findings of a 1983 prospective observational study,⁸ a 1991 randomized controlled trial (RCT),⁹ and a 1998 prospective observational study.² The 1983 and 1991 studies found higher rates of PIVC complications after day 2 of cannulation.^8,9 The 1998 study found no increase in the rate of complications after day 3 of catheterization, and its authors, recommending a reevaluation of the need to routinely replace PIVCs, wrote, “[The] hazard for catheter-related complications, phlebitis, catheter-related infections, and mechanical complications did not increase during prolonged catheterization.”²

Results of RCTs conducted by Barker et al.¹⁰ (2004) and Nishanth et al.¹¹ (2009) supported the claim that routine replacement of PIVCs leads to lower rates of thrombophlebitis. Nishanth et al. also included site pain and cannula dislodgement in their definition of phlebitis. Neither study compared blood stream infection rates, but both found higher rates of phlebitis between day 2.5 and day 3. However, Cochrane reviewers Webster et al.¹² questioned the findings of these 2 trials, given their missing data and possibly biased results and conclusions. In the Barker study, patient numbers (screened, eligible, dropout) were unclear; each patient group was unbalanced; protocol deviations were not reported (possibly a result of incomplete data reporting or inappropriate randomization); and varied definitions of phlebitis were allowed, which may have resulted in more events being included. In the Nishanth study, the 100% phlebitis rate for the clinically indicated replacement group seemed extreme, which suggested confounding by an unknown bias or chance. Last, both samples were small: 47 patients (Barker) and 42 patients (Nishanth). Given all these concerns, the 2 trials were excluded from the Cochrane meta-analysis on the subject.¹²

In the 1980s and early 1990s, routine removal and exchange of PIVCs were supported by limited evidence. Current well-designed trial data cast doubt on the need for such a practice.

WHY YOU SHOULD NOT ROUTINELY REPLACE PIVCs

According to the CDC,^6,7 the issue of routine PIVC replacement remains unresolved: “No recommendation is made regarding replacement of peripheral catheters in adults only when clinically indicated.”

Whereas earlier data showed a higher risk of complications with longer dwelling IVs, the majority of contemporary data has failed to support this conclusion. The recent (2015) Cochrane meta-analysis comparing routine with clinically indicated IVC replacement found “no evidence to support changing catheters every 72-96 hours.”¹² Of the 7 studies that fulfilled the criteria for qualitative analysis, only 5 were included (the studies by Barker et al.¹⁰ and Nishanth et al.¹¹ were excluded). The included studies assessed the endpoints of catheter-related blood stream infection (CRBSI), phlebitis, phlebitis per device-days, mortality, cost, and infiltration. Statistically significant differences were found only for cost (favoring clinically indicated replacement) and infiltration (occurring less with routine replacement). 

The largest and most robust RCT in the meta-analysis¹² was conducted by Rickard et al.¹³ (2012). Their nonblinded, intention-to-treat study of 3283 patients used concealed allocation to randomly assign patients to either clinically indicated or routine PIVC replacement in order to evaluate a primary endpoint, phlebitis. Secondary endpoints were CRBSI, venous port infection, IVC tip colonization, infusion failure, number of IVCs needed per patient, IV therapy duration, cost, and mortality. Need for PIVC replacement was methodically monitored (Table) with extensive nursing education and interrater validation. The study found no difference in the groups’ phlebitis rates; the rate was 7% for both routine and clinically indicated replacement (13.08% and 13.11%, respectively, adjusted for phlebitis per 1000 IVC days). In addition, there was no difference in the secondary outcome measures, except cost and number of catheters used, both of which favored clinically indicated replacement. The most serious complication, CRBSI, occurred at essentially the same rate in the 2 replacement arms: 0.11% (routine) and 0% (clinically indicated). Per-patient cost for the entire course of treatment was A$69.24 in the routine group and A$61.66 in the clinically indicated group; the difference was A$7.58 (P < 0.0001). Mean number of catheters used was 1.9 in the routine group and 1.7 in the clinically indicated group; the difference was 0.21 catheter per patient for the treatment course (P < 0.0001). Overall, the study found no important difference in significant outcomes between the 2 study arms.

The other 4 studies in the meta-analysis¹² duplicated these results, with none finding a higher rate of major adverse events.^14-17 All 4 showed virtually equivalent rates of phlebitis, the primary outcome; 3 also examined the secondary outcome measure of blood stream infection, and results were similar, with identical rates of complications. Only 1 trial identified any bloodstream infections (1 per group).¹⁵ The meta-analysis did find that routine catheter replacement resulted in less catheter infiltration. 

Most of the data on PIVC exchange involves phlebitis and other local complications. A prospective study by Stuart et al.¹⁸ and commentary by Collignon et al.¹⁹ underscore the need for further research targeting blood stream infections (sepsis and severe sepsis in particular) as a primary outcome. Blood stream infections, especially those related to PIVC use, are rare entities overall, with most recent data yielding an estimated rate of 0.5 per 1000 catheter-days.²⁰ Given this epidemiologic finding, researchers trying to acquire meaningful data on PIVC-related blood stream infections and subsequent complications would need to have tens of thousands of patients in routine and clinically indicated replacement arms to sufficiently power their studies.²⁰ As they are infeasible, such trials cannot be found in the scientific literature.

Stuart et al.¹⁸ tried addressing the question. Prospectively examining more than 5 million occupied-bed days and the incidence of bloodstream infections by type of intravascular device over a 5-year period, they found that 137 (23.5%) of 583 healthcare-associated Staphylococcus aureus bacteremia (SAB) cases were attributed to PIVC use. PIVC insertions were performed equally (39.6%) in emergency departments and medical wards. About 45% of PIVCs remained in place 4 days or longer. Stuart et al. noted the “significant issue of PIVC-associated SAB” and favored routine removal of PIVCs within 96 hours (4 days). However, 55% of patients in their PIVC-related SAB group had the device in place less than 4 days. In addition, overall incidence of SAB was low: 0.3 per 10,000 occupied-bed days. Further, their study did not adjust device-specific SAB incidence for frequency of device use. For example, the rate of healthcare-acquired SAB was 19.7% for central venous catheters and 23.5% for PIVCs, despite PIVCs being used significantly more often than central lines. Device-specific adjustments would show a vastly different absolute risk of SAB in relation to individual devices. Nevertheless, the overall benefit of and need for routine PIVC replacement must be questioned. The percentage of PIVC-associated SAB in their study and the need for more research in this area should be noted. Given current information, their study and others in the literature underscore the need for selective use, appropriate maintenance, and timely removal of PIVCs.

Pure clinical outcomes are important, but procedural costs are as well. Clinically indicated replacement helps patients avoid an unpleasant procedure and saves money.²¹ If one third of the 37 million annual inpatient admissions require a PIVC for more than 3 days, then a strategy of “replacement when clinically indicated” could prevent almost 2.5 million unnecessary PIVC insertions each year. Equipment cost savings combined with savings of nearly 1 million staff hours could yield an estimated $400 million in savings over a 5-year period.²² Given current data suggesting no harm from clinically indicated PIVC replacement and clear evidence that routine replacement increases needle sticks and costs, it seems time to end the practice of routine PIVC replacement.

Compared with clinically indicated catheter replacement, routine replacement in the absence of a clinical indication (eg, infiltration, phlebitis, infection) provides no added benefit. Studies have consistently found that rates of phlebitis and SAB are not affected by scheduled replacement, though the largest RCT may not have been powered to show a difference in SAB. The present authors’ recommendations for PIVC care are:

• Scrutinize each patient’s need for PIVCs and remove each PIVC as soon as possible.
• Do not make routine replacement of otherwise well-functioning, well-appearing clinically necessary PIVCs the standard of care.
• Regularly examine PIVC sites for signs and symptoms of infection.
• Remove a PIVC immediately on recognition of any clinical sign of a complication (eg, infiltration, phlebitis, localized infection, blood stream infection) and replace the PIVC only if there is a clinical need.
• If replacing PIVCs on a clinical basis, establish protocols for frequency of evaluation for complications; these protocols might mirror those from prior studies (Table).^10,22
• Replace as soon as possible any PIVC inserted during an urgent or emergent situation in which proper insertion technique could not be guaranteed.
• Conduct real-world observational studies to ensure that the switch to clinically driven replacement is safe and develop standardized definitions of complications.

Given the literature findings and the preceding recommendations, the authors conclude that the patient in the case example does not need routine PIVC replacement. His PIVC may remain in place as long as evaluation for local complications is routinely and methodically performed and the device is removed as soon as it is deemed unnecessary (transition to oral opioid therapy).

The long-standing practice of routinely replacing PIVCs every 72 to 96 hours during a hospital stay does not affect any meaningful clinical outcome. Specifically, data do not show that routine replacement prevents phlebitis or blood stream infections. Furthermore, routine PIVC replacement increases patient discomfort, uses resources unnecessarily, and raises hospital costs. Most of the PIVC research has involved phlebitis and other local complications; more research on PIVC use and bloodstream infections is needed. Given the findings in the current literature, routine PIVC replacement should be considered a Thing We Do For No Reason.

Disclosure

Nothing to report. 

Do you think this is a low-value practice? Is this truly a “Thing We Do for No Reason”? Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other “Things We Do for No Reason” topics by emailing [email protected].

We all know these patients:

The young man who, when his name shows up on the ED board, everyone lets out a little groan, knowing his hospital stay will be long and tumultuous.

The middle-aged woman who seems to do want your care and attention and yet rebuffs your attempts to help her, meanwhile, making constant demands on nursing staff.

The older man who trusts no one and will not cooperate with any of his needed care, frustrating staff and physicians alike.

Caring for the patient is integral to the art of doctoring, and yet, there are some people for whom this is incredibly hard to do. They frustrate even the most seasoned professional and work their way under our skin. While their disruptive acts may feel volitional to those of us attempting to provide care, these individuals may suffer from a personality disorder.

Megan Riddle, MD, PhD, is based in the department of psychiatry and behavioral sciences at the University of Washington, Seattle.

NOTES

1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA: American Psychiatric Association; 2013.

2. Riddle M, Meeks T, Alvarez C, Dubovsky A. When personality is the problem: Managing patients with difficult personalities on the acute care unit. J Hosp Med. 2016 Dec;11(12):873-878.

3. Bukh JD, Bock C, Kessing LV. Association between genetic polymorphisms in the serotonergic system and comorbid personality disorders among patients with first-episode depression. J Pers Disord. 2014 Jun;28(3):365-378.

4. Perez-Rodriguez MM, Weinstein S, New AS, et al. Tryptophan-hydroxylase 2 haplotype association with borderline personality disorder and aggression in a sample of patients with personality disorders and healthy controls. J Psychiatr Res. 2010 Nov; 44(15):1075-1081.

5. Checknita D, Maussion G, Labonte B, et al. Monoamine oxidase: A gene promoter methylation and transcriptional downregulation in an offender population with antisocial personality disorder. Br J Psychiatry. 2015 Mar;206(3):216-222.

6. Boen E, Westlye LT, Elvsashagen T, et al. Regional cortical thinning may be a biological marker for borderline personality disorder. Acta Psychiatr Scand. 2014 Sep;130(3):193-204.

7. Thoma P, Friedmann C, Suchan B. Empathy and social problem solving in alcohol dependence, mood disorders and selected personality disorders. Neurosci Biobehav Rev. 2013 Mar;37(3):448-470.

8. Liu H, Liao J, Jiang W, Wang W. Changes in low-frequency fluctuations in patients with antisocial personality disorder revealed by resting-state functional MRI. PLoS One. 2014 Mar 5;9(3):e89790.

9. Yang Y, Raine A. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: A meta-analysis. Psychiatry Res. 2009 Nov 30;174(2):81-88.

10. Fok ML, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res. 2012 Aug;73(2):104-107.

11. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet. 2015 Feb 21;385:717-726.

12. Groves JE. Taking care of the hateful patient. N Engl J Med. 1978 Apr 20; 298:883-887.

13. Groves JE. Management of the borderline patient on a medical or surgical ward: The psychiatric consultant’s role. Int J Psychiatry Med. 1975;6(3):337-348.

14. Bodner E, Cohen-Fridel S, Mashiah M, et al. The attitudes of psychiatric hospital staff toward hospitalization and treatment of patients with borderline personality disorder. BMC psychiatry. 2015 Jan 22;15:2.

15. Colli A, Tanzilli A, Dimaggio G, Lingiardi V. Patient personality and therapist response: An empirical investigation. Am J Psychiatry. 2014 Jan;171(1):102-108.

16. Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: Meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010 Jan;71(1):14-25.

We all know these patients:

The young man who, when his name shows up on the ED board, everyone lets out a little groan, knowing his hospital stay will be long and tumultuous.

The middle-aged woman who seems to do want your care and attention and yet rebuffs your attempts to help her, meanwhile, making constant demands on nursing staff.

The older man who trusts no one and will not cooperate with any of his needed care, frustrating staff and physicians alike.

Caring for the patient is integral to the art of doctoring, and yet, there are some people for whom this is incredibly hard to do. They frustrate even the most seasoned professional and work their way under our skin. While their disruptive acts may feel volitional to those of us attempting to provide care, these individuals may suffer from a personality disorder.

Megan Riddle, MD, PhD, is based in the department of psychiatry and behavioral sciences at the University of Washington, Seattle.

NOTES

1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA: American Psychiatric Association; 2013.

2. Riddle M, Meeks T, Alvarez C, Dubovsky A. When personality is the problem: Managing patients with difficult personalities on the acute care unit. J Hosp Med. 2016 Dec;11(12):873-878.

3. Bukh JD, Bock C, Kessing LV. Association between genetic polymorphisms in the serotonergic system and comorbid personality disorders among patients with first-episode depression. J Pers Disord. 2014 Jun;28(3):365-378.

4. Perez-Rodriguez MM, Weinstein S, New AS, et al. Tryptophan-hydroxylase 2 haplotype association with borderline personality disorder and aggression in a sample of patients with personality disorders and healthy controls. J Psychiatr Res. 2010 Nov; 44(15):1075-1081.

5. Checknita D, Maussion G, Labonte B, et al. Monoamine oxidase: A gene promoter methylation and transcriptional downregulation in an offender population with antisocial personality disorder. Br J Psychiatry. 2015 Mar;206(3):216-222.

6. Boen E, Westlye LT, Elvsashagen T, et al. Regional cortical thinning may be a biological marker for borderline personality disorder. Acta Psychiatr Scand. 2014 Sep;130(3):193-204.

7. Thoma P, Friedmann C, Suchan B. Empathy and social problem solving in alcohol dependence, mood disorders and selected personality disorders. Neurosci Biobehav Rev. 2013 Mar;37(3):448-470.

8. Liu H, Liao J, Jiang W, Wang W. Changes in low-frequency fluctuations in patients with antisocial personality disorder revealed by resting-state functional MRI. PLoS One. 2014 Mar 5;9(3):e89790.

9. Yang Y, Raine A. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: A meta-analysis. Psychiatry Res. 2009 Nov 30;174(2):81-88.

10. Fok ML, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res. 2012 Aug;73(2):104-107.

11. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet. 2015 Feb 21;385:717-726.

12. Groves JE. Taking care of the hateful patient. N Engl J Med. 1978 Apr 20; 298:883-887.

13. Groves JE. Management of the borderline patient on a medical or surgical ward: The psychiatric consultant’s role. Int J Psychiatry Med. 1975;6(3):337-348.

14. Bodner E, Cohen-Fridel S, Mashiah M, et al. The attitudes of psychiatric hospital staff toward hospitalization and treatment of patients with borderline personality disorder. BMC psychiatry. 2015 Jan 22;15:2.

15. Colli A, Tanzilli A, Dimaggio G, Lingiardi V. Patient personality and therapist response: An empirical investigation. Am J Psychiatry. 2014 Jan;171(1):102-108.

16. Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: Meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010 Jan;71(1):14-25.

We all know these patients:

The young man who, when his name shows up on the ED board, everyone lets out a little groan, knowing his hospital stay will be long and tumultuous.

The middle-aged woman who seems to do want your care and attention and yet rebuffs your attempts to help her, meanwhile, making constant demands on nursing staff.

The older man who trusts no one and will not cooperate with any of his needed care, frustrating staff and physicians alike.

Caring for the patient is integral to the art of doctoring, and yet, there are some people for whom this is incredibly hard to do. They frustrate even the most seasoned professional and work their way under our skin. While their disruptive acts may feel volitional to those of us attempting to provide care, these individuals may suffer from a personality disorder.

Megan Riddle, MD, PhD, is based in the department of psychiatry and behavioral sciences at the University of Washington, Seattle.

NOTES

1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA: American Psychiatric Association; 2013.

2. Riddle M, Meeks T, Alvarez C, Dubovsky A. When personality is the problem: Managing patients with difficult personalities on the acute care unit. J Hosp Med. 2016 Dec;11(12):873-878.

3. Bukh JD, Bock C, Kessing LV. Association between genetic polymorphisms in the serotonergic system and comorbid personality disorders among patients with first-episode depression. J Pers Disord. 2014 Jun;28(3):365-378.

4. Perez-Rodriguez MM, Weinstein S, New AS, et al. Tryptophan-hydroxylase 2 haplotype association with borderline personality disorder and aggression in a sample of patients with personality disorders and healthy controls. J Psychiatr Res. 2010 Nov; 44(15):1075-1081.

5. Checknita D, Maussion G, Labonte B, et al. Monoamine oxidase: A gene promoter methylation and transcriptional downregulation in an offender population with antisocial personality disorder. Br J Psychiatry. 2015 Mar;206(3):216-222.

6. Boen E, Westlye LT, Elvsashagen T, et al. Regional cortical thinning may be a biological marker for borderline personality disorder. Acta Psychiatr Scand. 2014 Sep;130(3):193-204.

7. Thoma P, Friedmann C, Suchan B. Empathy and social problem solving in alcohol dependence, mood disorders and selected personality disorders. Neurosci Biobehav Rev. 2013 Mar;37(3):448-470.

8. Liu H, Liao J, Jiang W, Wang W. Changes in low-frequency fluctuations in patients with antisocial personality disorder revealed by resting-state functional MRI. PLoS One. 2014 Mar 5;9(3):e89790.

9. Yang Y, Raine A. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: A meta-analysis. Psychiatry Res. 2009 Nov 30;174(2):81-88.

10. Fok ML, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res. 2012 Aug;73(2):104-107.

11. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet. 2015 Feb 21;385:717-726.

12. Groves JE. Taking care of the hateful patient. N Engl J Med. 1978 Apr 20; 298:883-887.

13. Groves JE. Management of the borderline patient on a medical or surgical ward: The psychiatric consultant’s role. Int J Psychiatry Med. 1975;6(3):337-348.

14. Bodner E, Cohen-Fridel S, Mashiah M, et al. The attitudes of psychiatric hospital staff toward hospitalization and treatment of patients with borderline personality disorder. BMC psychiatry. 2015 Jan 22;15:2.

15. Colli A, Tanzilli A, Dimaggio G, Lingiardi V. Patient personality and therapist response: An empirical investigation. Am J Psychiatry. 2014 Jan;171(1):102-108.

16. Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: Meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010 Jan;71(1):14-25.

ORLANDO – Preclinical studies and years of clinical experience using the monoclonal antibody ustekinumab (Stelara, Janssen Biotech) in psoriasis and psoriatic arthritis offer important clues to any gastroenterologist perplexed by the official Food and Drug Administration indication, dosing frequency, and intensity for Crohn’s disease. Phase II and phase III findings also reveal where the monoclonal antibody may offer particular advantages, compared with other agents.

“Ustekinumab landed in your lap in September. You’re probably all trying to figure out how to get the ID formulation paid for with insurance,” William J. Sanborn, MD, professor and chief of the division of gastroenterology at the University of California, San Diego, said at the Advances in Inflammatory Bowel Diseases meeting. “But this is now the reality that you have this in your Crohn’s practice.”

The FDA approved ustekinumab to treat adults with moderately to severely active Crohn’s disease who 1) failed or were intolerant to immune modulators or corticosteroids but did not fail tumor necrosis factor (TNF) blockers or 2) failed or were intolerant to one or more TNF blockers. Dr. Sanborn and colleagues observed a significant induction of clinical response in a subgroup of patients who previously failed a TNF blocker in an early efficacy study (Gastroenterology. 2008;135:1130-41). “This is where the idea of initially focusing on TNF failures came from,” he added at the meeting sponsored by the Crohn’s & Colitis Foundation of America.

Induction dosing in Crohn’s disease is intravenous versus subcutaneous in psoriasis and psoriatic arthritis, in part because of the same study. “It looked like relatively better bioavailability and relatively better effect with intravenous dosing,” Dr. Sanborn said. “In Crohn’s disease, it’s a completely different animal.”
 

Official induction dosing is approximately 6 mg/kg in three fixed doses according to patient weight in Crohn’s disease. The 6-mg/kg dose yielded the most consistent response, compared with 1-mg/kg or 3-mg/kg doses in a subsequent phase IIb study (N Engl J Med. 2012;367:1519-28).

The most consistent induction results at weeks 6 and 8 were observed with 6 mg/kg ustekinumab versus 1 mg/kg or 3 mg/kg.

Dr. Sanborn and coinvestigators also saw “numeric differences in drug versus placebo for remission at 6 and 8 weeks “but it was not that clear from the phase II trial what the remission efficacy was, so that needed more exploration to really understand.”

Another distinction for ustekinumab in Crohn’s disease is the approved maintenance dosing of 90 mg subcutaneously every 8 weeks versus a 12-week interval recommended for psoriasis. “Why so much more in Crohn’s disease, and is that necessary?” Dr. Sanborn asked.

Based on changes in C-reactive protein levels and a “rapid drop” in Crohn’s Disease Activity Index scores by 4 weeks, “clearly efficacy was there for induction,” he said. Ustekinumab has a “quick onset – analogous to the TNF blockers.”

“These were quite encouraging data, and paved the way to move on to phase III [studies],” Dr. Sanborn said. The preclinical studies up to this point focused on patients with Crohn’s disease who previously failed TNF blockers. However, “in clinical practice, we would be interested to know if it would work in anti-TNF naive or nonfailures as well.”

So two subsequent studies assessed safety and efficacy in a TNF blocker–failure population (UNITI-1 trial. Inflamm. Bowel Dis. 2016 Mar;22 Suppl 1:S1) and a non-TNF failure population of patients who did fail previous conventional therapy such as steroids or immunomodulators (UNITI-2 trial).

Clinical response and remission steadily rose following induction up to a significant difference versus placebo at 8 weeks in the non–TNF failure population. “Remember, in the phase IIa study, the remission rates were not as clear-cut, so this really nails down this as a good drug in both patient populations,” Dr. Sanborn said.

To evaluate long-term maintenance, investigators rerandomized all participants in the UNITI-1 and UNITI-2 studies. They saw a 15% gain in clinical remission out to week 44, compared with placebo. Dr. Sanborn noted that ustekinumab has a relatively long half-life, so the difference in patients switched to placebo may not have been as striking. “In practice it’s important to know the on-time and off-time of this agent, and I think the clinical trials make that clear.”

The trials also show that 12-week dosing works, Dr. Sanborn said. “You see about 20% gain for every 8-week dosing. You get extra 5% or 10% extra on all outcome measures at 8 weeks, compared to 12 weeks dosing, with no difference in safety signals.” He added, “So more intensive dosing of 90 mg every 8 weeks is what ended up getting approved in the United States.”
 

Safety profile

So what does all the preclinical evidence suggest about safety of ustekinumab? The UNITI trials combined included more than 1,000 patients, and there were no deaths, Dr. Sanborn said. “Usually with TNF blockers in 1,000 patients you would see a few deaths.”

Patient withdrawals from the preclinical studies were also relatively low, Dr. Sanborn reported. “With ustekinumab monotherapy, drug withdrawal is only 3% or 4%, so it seems to be different from TNF blockers in that sense [too].”

In addition, the rates of adverse events were similar between placebo (83.5%) and ustekinumab’s combined every 8 week and every 12 week dosing groups through 44 weeks (81.0%), Dr. Sanborn said. The rates of serious adverse events were likewise similar, 15.0% and 11.0%, respectively. Reported malignancy included two cases of basal cell skin cancers, one in the placebo group and one in the every-8-week dosing group, he added.

“So all those black box warnings you’re used to worrying about with TNF blockers – serious infections, about opportunistic infections, malignancy – there is no black box warning with this agent around that.”

Dr. Sanborn noted that the FDA labeling reports infections. “We know Crohn’s disease patients are [also] getting azathioprine, steroids, methotrexate, so you will see some infections, but there wasn’t a consistent opportunistic infection signal.”

One case of reversible posterior leukoencephalopathy syndrome is included on the labeling. Dr. Sanborn also put this in perspective: “With all the experience in psoriasis and psoriatic arthritis, and the clinical trials [in IBD], there is just one case. So the relationship is not very clear.”

“The safety signals with ustekinumab are really very good. It seems to be an extremely safe agent – we really don’t see much in terms of infections,” Brian Feagan, MD, an internist and gastroenterologist at the University of Western Ontario in London, said in a separate presentation at the conference. “We don’t have a lot of long-term experience with ustekinumab in Crohn’s disease, but we have a lot of experience in psoriasis, and it’s a safe drug.”

“Ustekinumab may be our first really valid monotherapy, with less immunogenicity,” Dr. Feagan said.

AGA Resource

AGA offers an IBD Clinical Service Line that provides tools to help you become more efficient, understand quality standards, and improve the process of care for patients. Learn more at http://www.gastro.org/patient-care/conditions-diseases/ibd

ORLANDO – Preclinical studies and years of clinical experience using the monoclonal antibody ustekinumab (Stelara, Janssen Biotech) in psoriasis and psoriatic arthritis offer important clues to any gastroenterologist perplexed by the official Food and Drug Administration indication, dosing frequency, and intensity for Crohn’s disease. Phase II and phase III findings also reveal where the monoclonal antibody may offer particular advantages, compared with other agents.

“Ustekinumab landed in your lap in September. You’re probably all trying to figure out how to get the ID formulation paid for with insurance,” William J. Sanborn, MD, professor and chief of the division of gastroenterology at the University of California, San Diego, said at the Advances in Inflammatory Bowel Diseases meeting. “But this is now the reality that you have this in your Crohn’s practice.”

The FDA approved ustekinumab to treat adults with moderately to severely active Crohn’s disease who 1) failed or were intolerant to immune modulators or corticosteroids but did not fail tumor necrosis factor (TNF) blockers or 2) failed or were intolerant to one or more TNF blockers. Dr. Sanborn and colleagues observed a significant induction of clinical response in a subgroup of patients who previously failed a TNF blocker in an early efficacy study (Gastroenterology. 2008;135:1130-41). “This is where the idea of initially focusing on TNF failures came from,” he added at the meeting sponsored by the Crohn’s & Colitis Foundation of America.

Induction dosing in Crohn’s disease is intravenous versus subcutaneous in psoriasis and psoriatic arthritis, in part because of the same study. “It looked like relatively better bioavailability and relatively better effect with intravenous dosing,” Dr. Sanborn said. “In Crohn’s disease, it’s a completely different animal.”
 

Official induction dosing is approximately 6 mg/kg in three fixed doses according to patient weight in Crohn’s disease. The 6-mg/kg dose yielded the most consistent response, compared with 1-mg/kg or 3-mg/kg doses in a subsequent phase IIb study (N Engl J Med. 2012;367:1519-28).

The most consistent induction results at weeks 6 and 8 were observed with 6 mg/kg ustekinumab versus 1 mg/kg or 3 mg/kg.

Dr. Sanborn and coinvestigators also saw “numeric differences in drug versus placebo for remission at 6 and 8 weeks “but it was not that clear from the phase II trial what the remission efficacy was, so that needed more exploration to really understand.”

Another distinction for ustekinumab in Crohn’s disease is the approved maintenance dosing of 90 mg subcutaneously every 8 weeks versus a 12-week interval recommended for psoriasis. “Why so much more in Crohn’s disease, and is that necessary?” Dr. Sanborn asked.

Based on changes in C-reactive protein levels and a “rapid drop” in Crohn’s Disease Activity Index scores by 4 weeks, “clearly efficacy was there for induction,” he said. Ustekinumab has a “quick onset – analogous to the TNF blockers.”

“These were quite encouraging data, and paved the way to move on to phase III [studies],” Dr. Sanborn said. The preclinical studies up to this point focused on patients with Crohn’s disease who previously failed TNF blockers. However, “in clinical practice, we would be interested to know if it would work in anti-TNF naive or nonfailures as well.”

So two subsequent studies assessed safety and efficacy in a TNF blocker–failure population (UNITI-1 trial. Inflamm. Bowel Dis. 2016 Mar;22 Suppl 1:S1) and a non-TNF failure population of patients who did fail previous conventional therapy such as steroids or immunomodulators (UNITI-2 trial).

Clinical response and remission steadily rose following induction up to a significant difference versus placebo at 8 weeks in the non–TNF failure population. “Remember, in the phase IIa study, the remission rates were not as clear-cut, so this really nails down this as a good drug in both patient populations,” Dr. Sanborn said.

To evaluate long-term maintenance, investigators rerandomized all participants in the UNITI-1 and UNITI-2 studies. They saw a 15% gain in clinical remission out to week 44, compared with placebo. Dr. Sanborn noted that ustekinumab has a relatively long half-life, so the difference in patients switched to placebo may not have been as striking. “In practice it’s important to know the on-time and off-time of this agent, and I think the clinical trials make that clear.”

The trials also show that 12-week dosing works, Dr. Sanborn said. “You see about 20% gain for every 8-week dosing. You get extra 5% or 10% extra on all outcome measures at 8 weeks, compared to 12 weeks dosing, with no difference in safety signals.” He added, “So more intensive dosing of 90 mg every 8 weeks is what ended up getting approved in the United States.”
 

Safety profile

So what does all the preclinical evidence suggest about safety of ustekinumab? The UNITI trials combined included more than 1,000 patients, and there were no deaths, Dr. Sanborn said. “Usually with TNF blockers in 1,000 patients you would see a few deaths.”

Patient withdrawals from the preclinical studies were also relatively low, Dr. Sanborn reported. “With ustekinumab monotherapy, drug withdrawal is only 3% or 4%, so it seems to be different from TNF blockers in that sense [too].”

In addition, the rates of adverse events were similar between placebo (83.5%) and ustekinumab’s combined every 8 week and every 12 week dosing groups through 44 weeks (81.0%), Dr. Sanborn said. The rates of serious adverse events were likewise similar, 15.0% and 11.0%, respectively. Reported malignancy included two cases of basal cell skin cancers, one in the placebo group and one in the every-8-week dosing group, he added.

“So all those black box warnings you’re used to worrying about with TNF blockers – serious infections, about opportunistic infections, malignancy – there is no black box warning with this agent around that.”

Dr. Sanborn noted that the FDA labeling reports infections. “We know Crohn’s disease patients are [also] getting azathioprine, steroids, methotrexate, so you will see some infections, but there wasn’t a consistent opportunistic infection signal.”

One case of reversible posterior leukoencephalopathy syndrome is included on the labeling. Dr. Sanborn also put this in perspective: “With all the experience in psoriasis and psoriatic arthritis, and the clinical trials [in IBD], there is just one case. So the relationship is not very clear.”

“The safety signals with ustekinumab are really very good. It seems to be an extremely safe agent – we really don’t see much in terms of infections,” Brian Feagan, MD, an internist and gastroenterologist at the University of Western Ontario in London, said in a separate presentation at the conference. “We don’t have a lot of long-term experience with ustekinumab in Crohn’s disease, but we have a lot of experience in psoriasis, and it’s a safe drug.”

“Ustekinumab may be our first really valid monotherapy, with less immunogenicity,” Dr. Feagan said.

AGA Resource

AGA offers an IBD Clinical Service Line that provides tools to help you become more efficient, understand quality standards, and improve the process of care for patients. Learn more at http://www.gastro.org/patient-care/conditions-diseases/ibd

ORLANDO – Preclinical studies and years of clinical experience using the monoclonal antibody ustekinumab (Stelara, Janssen Biotech) in psoriasis and psoriatic arthritis offer important clues to any gastroenterologist perplexed by the official Food and Drug Administration indication, dosing frequency, and intensity for Crohn’s disease. Phase II and phase III findings also reveal where the monoclonal antibody may offer particular advantages, compared with other agents.

“Ustekinumab landed in your lap in September. You’re probably all trying to figure out how to get the ID formulation paid for with insurance,” William J. Sanborn, MD, professor and chief of the division of gastroenterology at the University of California, San Diego, said at the Advances in Inflammatory Bowel Diseases meeting. “But this is now the reality that you have this in your Crohn’s practice.”

The FDA approved ustekinumab to treat adults with moderately to severely active Crohn’s disease who 1) failed or were intolerant to immune modulators or corticosteroids but did not fail tumor necrosis factor (TNF) blockers or 2) failed or were intolerant to one or more TNF blockers. Dr. Sanborn and colleagues observed a significant induction of clinical response in a subgroup of patients who previously failed a TNF blocker in an early efficacy study (Gastroenterology. 2008;135:1130-41). “This is where the idea of initially focusing on TNF failures came from,” he added at the meeting sponsored by the Crohn’s & Colitis Foundation of America.

Induction dosing in Crohn’s disease is intravenous versus subcutaneous in psoriasis and psoriatic arthritis, in part because of the same study. “It looked like relatively better bioavailability and relatively better effect with intravenous dosing,” Dr. Sanborn said. “In Crohn’s disease, it’s a completely different animal.”
 

Official induction dosing is approximately 6 mg/kg in three fixed doses according to patient weight in Crohn’s disease. The 6-mg/kg dose yielded the most consistent response, compared with 1-mg/kg or 3-mg/kg doses in a subsequent phase IIb study (N Engl J Med. 2012;367:1519-28).

The most consistent induction results at weeks 6 and 8 were observed with 6 mg/kg ustekinumab versus 1 mg/kg or 3 mg/kg.

Dr. Sanborn and coinvestigators also saw “numeric differences in drug versus placebo for remission at 6 and 8 weeks “but it was not that clear from the phase II trial what the remission efficacy was, so that needed more exploration to really understand.”

Another distinction for ustekinumab in Crohn’s disease is the approved maintenance dosing of 90 mg subcutaneously every 8 weeks versus a 12-week interval recommended for psoriasis. “Why so much more in Crohn’s disease, and is that necessary?” Dr. Sanborn asked.

Based on changes in C-reactive protein levels and a “rapid drop” in Crohn’s Disease Activity Index scores by 4 weeks, “clearly efficacy was there for induction,” he said. Ustekinumab has a “quick onset – analogous to the TNF blockers.”

“These were quite encouraging data, and paved the way to move on to phase III [studies],” Dr. Sanborn said. The preclinical studies up to this point focused on patients with Crohn’s disease who previously failed TNF blockers. However, “in clinical practice, we would be interested to know if it would work in anti-TNF naive or nonfailures as well.”

So two subsequent studies assessed safety and efficacy in a TNF blocker–failure population (UNITI-1 trial. Inflamm. Bowel Dis. 2016 Mar;22 Suppl 1:S1) and a non-TNF failure population of patients who did fail previous conventional therapy such as steroids or immunomodulators (UNITI-2 trial).

Clinical response and remission steadily rose following induction up to a significant difference versus placebo at 8 weeks in the non–TNF failure population. “Remember, in the phase IIa study, the remission rates were not as clear-cut, so this really nails down this as a good drug in both patient populations,” Dr. Sanborn said.

To evaluate long-term maintenance, investigators rerandomized all participants in the UNITI-1 and UNITI-2 studies. They saw a 15% gain in clinical remission out to week 44, compared with placebo. Dr. Sanborn noted that ustekinumab has a relatively long half-life, so the difference in patients switched to placebo may not have been as striking. “In practice it’s important to know the on-time and off-time of this agent, and I think the clinical trials make that clear.”

The trials also show that 12-week dosing works, Dr. Sanborn said. “You see about 20% gain for every 8-week dosing. You get extra 5% or 10% extra on all outcome measures at 8 weeks, compared to 12 weeks dosing, with no difference in safety signals.” He added, “So more intensive dosing of 90 mg every 8 weeks is what ended up getting approved in the United States.”
 

Safety profile

So what does all the preclinical evidence suggest about safety of ustekinumab? The UNITI trials combined included more than 1,000 patients, and there were no deaths, Dr. Sanborn said. “Usually with TNF blockers in 1,000 patients you would see a few deaths.”

Patient withdrawals from the preclinical studies were also relatively low, Dr. Sanborn reported. “With ustekinumab monotherapy, drug withdrawal is only 3% or 4%, so it seems to be different from TNF blockers in that sense [too].”

In addition, the rates of adverse events were similar between placebo (83.5%) and ustekinumab’s combined every 8 week and every 12 week dosing groups through 44 weeks (81.0%), Dr. Sanborn said. The rates of serious adverse events were likewise similar, 15.0% and 11.0%, respectively. Reported malignancy included two cases of basal cell skin cancers, one in the placebo group and one in the every-8-week dosing group, he added.

“So all those black box warnings you’re used to worrying about with TNF blockers – serious infections, about opportunistic infections, malignancy – there is no black box warning with this agent around that.”

Dr. Sanborn noted that the FDA labeling reports infections. “We know Crohn’s disease patients are [also] getting azathioprine, steroids, methotrexate, so you will see some infections, but there wasn’t a consistent opportunistic infection signal.”

One case of reversible posterior leukoencephalopathy syndrome is included on the labeling. Dr. Sanborn also put this in perspective: “With all the experience in psoriasis and psoriatic arthritis, and the clinical trials [in IBD], there is just one case. So the relationship is not very clear.”

“The safety signals with ustekinumab are really very good. It seems to be an extremely safe agent – we really don’t see much in terms of infections,” Brian Feagan, MD, an internist and gastroenterologist at the University of Western Ontario in London, said in a separate presentation at the conference. “We don’t have a lot of long-term experience with ustekinumab in Crohn’s disease, but we have a lot of experience in psoriasis, and it’s a safe drug.”

“Ustekinumab may be our first really valid monotherapy, with less immunogenicity,” Dr. Feagan said.

AGA Resource

AGA offers an IBD Clinical Service Line that provides tools to help you become more efficient, understand quality standards, and improve the process of care for patients. Learn more at http://www.gastro.org/patient-care/conditions-diseases/ibd

A clinical practice guideline for diagnosing pulmonary, extrapulmonary, and latent tuberculosis in adults and children has been released jointly by the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America.

The American Academy of Pediatrics also provided input to the guideline, which includes 23 evidence-based recommendations. The document is intended to assist clinicians in high-resource countries with a low incidence of TB disease and latent TB infection, such as the United States, said David M. Lewinsohn, MD, PhD, and his associates on the joint task force that wrote the guideline.

Zerbor/Thinkstock

• Both liquid and solid mycobacterial cultures should be performed on every specimen from patients suspected of having TB disease, rather than either type alone.

• A diagnostic nucleic acid amplification test should be performed on the initial specimen from patients suspected of having pulmonary TB.

• Rapid molecular drug susceptibility testing of respiratory specimens is advised for certain patients, with a focus on testing for rifampin susceptibility with or without isoniazid.

• Patients suspected of having extrapulmonary TB also should have mycobacterial cultures performed on all specimens.

• For all mycobacterial cultures that are positive for TB, a culture isolate should be submitted for genotyping to a regional genotyping laboratory.

• For patients aged 5 and older who are suspected of having latent TB infection, an interferon-gamma release assay (IGRA) is advised rather than a tuberculin skin test, especially if the patient is not likely to return to have the test result read. A tuberculin skin test is an acceptable alternative if IGRA is not available, is too expensive, or is too burdensome.

The guideline also addresses bronchoscopic sampling, cell counts and chemistries from fluid specimens collected from sites suspected of harboring extrapulmonary TB (such as pleural, cerebrospinal, ascetic, or joint fluids), and measurement of adenosine deaminase levels.

This work was supported by the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America, with input from the American Academy of Pediatrics. Dr. Lewinsohn reported having no relevant financial disclosures; his associates reported ties to numerous industry sources.

A clinical practice guideline for diagnosing pulmonary, extrapulmonary, and latent tuberculosis in adults and children has been released jointly by the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America.

The American Academy of Pediatrics also provided input to the guideline, which includes 23 evidence-based recommendations. The document is intended to assist clinicians in high-resource countries with a low incidence of TB disease and latent TB infection, such as the United States, said David M. Lewinsohn, MD, PhD, and his associates on the joint task force that wrote the guideline.

Zerbor/Thinkstock

• Both liquid and solid mycobacterial cultures should be performed on every specimen from patients suspected of having TB disease, rather than either type alone.

• A diagnostic nucleic acid amplification test should be performed on the initial specimen from patients suspected of having pulmonary TB.

• Rapid molecular drug susceptibility testing of respiratory specimens is advised for certain patients, with a focus on testing for rifampin susceptibility with or without isoniazid.

• Patients suspected of having extrapulmonary TB also should have mycobacterial cultures performed on all specimens.

• For all mycobacterial cultures that are positive for TB, a culture isolate should be submitted for genotyping to a regional genotyping laboratory.

• For patients aged 5 and older who are suspected of having latent TB infection, an interferon-gamma release assay (IGRA) is advised rather than a tuberculin skin test, especially if the patient is not likely to return to have the test result read. A tuberculin skin test is an acceptable alternative if IGRA is not available, is too expensive, or is too burdensome.

The guideline also addresses bronchoscopic sampling, cell counts and chemistries from fluid specimens collected from sites suspected of harboring extrapulmonary TB (such as pleural, cerebrospinal, ascetic, or joint fluids), and measurement of adenosine deaminase levels.

This work was supported by the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America, with input from the American Academy of Pediatrics. Dr. Lewinsohn reported having no relevant financial disclosures; his associates reported ties to numerous industry sources.

A clinical practice guideline for diagnosing pulmonary, extrapulmonary, and latent tuberculosis in adults and children has been released jointly by the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America.

The American Academy of Pediatrics also provided input to the guideline, which includes 23 evidence-based recommendations. The document is intended to assist clinicians in high-resource countries with a low incidence of TB disease and latent TB infection, such as the United States, said David M. Lewinsohn, MD, PhD, and his associates on the joint task force that wrote the guideline.

Zerbor/Thinkstock

• Both liquid and solid mycobacterial cultures should be performed on every specimen from patients suspected of having TB disease, rather than either type alone.

• A diagnostic nucleic acid amplification test should be performed on the initial specimen from patients suspected of having pulmonary TB.

• Rapid molecular drug susceptibility testing of respiratory specimens is advised for certain patients, with a focus on testing for rifampin susceptibility with or without isoniazid.

• Patients suspected of having extrapulmonary TB also should have mycobacterial cultures performed on all specimens.

• For all mycobacterial cultures that are positive for TB, a culture isolate should be submitted for genotyping to a regional genotyping laboratory.

• For patients aged 5 and older who are suspected of having latent TB infection, an interferon-gamma release assay (IGRA) is advised rather than a tuberculin skin test, especially if the patient is not likely to return to have the test result read. A tuberculin skin test is an acceptable alternative if IGRA is not available, is too expensive, or is too burdensome.

The guideline also addresses bronchoscopic sampling, cell counts and chemistries from fluid specimens collected from sites suspected of harboring extrapulmonary TB (such as pleural, cerebrospinal, ascetic, or joint fluids), and measurement of adenosine deaminase levels.

This work was supported by the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America, with input from the American Academy of Pediatrics. Dr. Lewinsohn reported having no relevant financial disclosures; his associates reported ties to numerous industry sources.

Non-MD cardiothoracic team professionals can submit a scientific poster for the Perioperative/Team-Based Care Poster Competition. Winning posters will be displayed at the AATS Centennial, April 29 – May 3 in Boston, MA.

The competition winner will receive a $1,000 stipend to offset travel and accommodation costs.

Deadline: January 20, 2017 

More information 

Share:

Non-MD cardiothoracic team professionals can submit a scientific poster for the Perioperative/Team-Based Care Poster Competition. Winning posters will be displayed at the AATS Centennial, April 29 – May 3 in Boston, MA.

The competition winner will receive a $1,000 stipend to offset travel and accommodation costs.

Deadline: January 20, 2017 

More information 

Share:

Non-MD cardiothoracic team professionals can submit a scientific poster for the Perioperative/Team-Based Care Poster Competition. Winning posters will be displayed at the AATS Centennial, April 29 – May 3 in Boston, MA.

The competition winner will receive a $1,000 stipend to offset travel and accommodation costs.

Deadline: January 20, 2017 

More information 

Share:

Non-MD cardiothoracic team professionals can submit a scientific poster for the Perioperative/Team-Based Care Poster Competition. Winning posters will be displayed at the AATS Centennial, April 29 – May 3 in Boston, MA.

The competition winner will receive a $1,000 stipend to offset travel and accommodation costs.

Deadline: January 20, 2017 

More information 

Share:

Non-MD cardiothoracic team professionals can submit a scientific poster for the Perioperative/Team-Based Care Poster Competition. Winning posters will be displayed at the AATS Centennial, April 29 – May 3 in Boston, MA.

The competition winner will receive a $1,000 stipend to offset travel and accommodation costs.

Deadline: January 20, 2017 

More information 

Share:

Non-MD cardiothoracic team professionals can submit a scientific poster for the Perioperative/Team-Based Care Poster Competition. Winning posters will be displayed at the AATS Centennial, April 29 – May 3 in Boston, MA.

The competition winner will receive a $1,000 stipend to offset travel and accommodation costs.

Deadline: January 20, 2017 

More information 

Share:

The antisense oligonucleotide drug nusinersen is the first therapy approved by the U.S. Food and Drug Administration to treat children and adults with spinal muscular atrophy.

The drug was developed by Ionis Pharmaceuticals and will be marketed by Biogen under the brand name Spinraza. The antisense oligonucleotide drug is administered via an intrathecal injection and promotes transcription of the full-length survival motor neuron (SMN) protein from the SMN2 gene.

[email protected]

The antisense oligonucleotide drug nusinersen is the first therapy approved by the U.S. Food and Drug Administration to treat children and adults with spinal muscular atrophy.

The drug was developed by Ionis Pharmaceuticals and will be marketed by Biogen under the brand name Spinraza. The antisense oligonucleotide drug is administered via an intrathecal injection and promotes transcription of the full-length survival motor neuron (SMN) protein from the SMN2 gene.

[email protected]

The antisense oligonucleotide drug nusinersen is the first therapy approved by the U.S. Food and Drug Administration to treat children and adults with spinal muscular atrophy.

The drug was developed by Ionis Pharmaceuticals and will be marketed by Biogen under the brand name Spinraza. The antisense oligonucleotide drug is administered via an intrathecal injection and promotes transcription of the full-length survival motor neuron (SMN) protein from the SMN2 gene.

[email protected]

NEW ORLEANS – Therapy with cells known to repair ischemic damage does not improve intermittent claudication of the legs in unselected patients, according to data from the randomized, phase II PACE trial reported at the American Heart Association scientific sessions. But some patients had evidence of new vessel formation.

“Administration of ALDH [aldehyde dehydrogenase] bright cells was feasible and safe, [but] administration at this dose and in this PAD [peripheral artery disease] cohort did not change peak walking time or MRI-based anatomic and perfusion endpoints,” reported Emerson C. Perin, MD, director of Clinical Research for Cardiovascular Medicine and medical director of the Stem Cell Center, both at the Texas Heart Institute, Houston.

Dr. Perin replied: “PAD is kind of the stepchild of cardiovascular medicine, it’s very poorly understood. And I think with the PACE trial, we’ve actually taken a huge step in understanding how we can treat these patients and how to study these patients.”

“Even though intermittent claudication or PAD starts with the flow limitation, what you wind up getting later down the road is not something that just relates to flow,” he elaborated. “We were able to study flow completely in this study – we owned it. What we weren’t able to study, and at the time we couldn’t, but now we can, is the metabolic, endothelial, and mitochondrial function. That is, what’s happening at the level of the muscle that is the missing link, together with the flow, that will give us these answers. So I think PACE [Patients With Intermittent Claudication Injected With ALDH Bright Cells] was very important to give us a greater understanding of where we can go now in PAD research.”

Trial details

Between 1 and 3 million people in the United States live with claudication, Dr. Perin noted when introducing the study. “It’s a very significant problem and a problem for which we really don’t have good solutions. We have one medicine [cilostazol], revascularization surgery, and stents that have recurrence – things that are less than perfect. There are also exercise programs, which not everyone has access to.”

The ALDH bright cells tested in PACE are collected from a patient’s bone marrow and express high levels of that enzyme. They are enriched for hematopoietic, endothelial progenitor, and multipotent mesenchymal colony-forming cells, and have shown ischemic repair capacity in preclinical models, with an increase in capillary density.

The investigators enrolled 82 patients with atherosclerotic peripheral arterial disease and symptom-limiting intermittent claudication of the legs. All had a pre-exercise ankle-brachial index of less than 0.9 or a pre-exercise toe-brachial index of less than 0.7, as well as stenosis greater than 50% or occlusion of infra-inguinal arteries by advanced imaging.

The patients were treated with 10 1-mL injections of ALDH bright cells or placebo into muscles of the posterior lower thigh and calf.

Results showed that after 6 months, peak treadmill walking time had improved by 2.2 minutes in the cell therapy group and 1.2 minutes in the placebo group, but the difference was not significant, Dr. Perin reported. The groups also were statistically indistinguishable overall with respect to changes in ankle-brachial index, walking impairment, and symptoms, and in MRI-assessed collateral count, peak hyperemic flow in the popliteal artery, and capillary perfusion.

However, among the subgroup of patients having a pre-exercise ankle-brachial index of 0.6 or less at baseline, collateral count increased by 2.4 in the cell therapy group, compared with 0.5 in the placebo group (P = .021).

In addition, among patients who had occluded femoral arteries at baseline (having more collateral vessels than peers with patent femoral arteries), the number of collaterals increased by 1.5 in the cell therapy group, compared with 0.3 in the placebo group (P = .047).

“This suggests an arteriogenic effect of cell therapy in patients with an occluded femoral artery substrate,” said Dr. Perin, who disclosed that he received a research grant from the National Heart, Lung, and Blood Institute.

NEW ORLEANS – Therapy with cells known to repair ischemic damage does not improve intermittent claudication of the legs in unselected patients, according to data from the randomized, phase II PACE trial reported at the American Heart Association scientific sessions. But some patients had evidence of new vessel formation.

“Administration of ALDH [aldehyde dehydrogenase] bright cells was feasible and safe, [but] administration at this dose and in this PAD [peripheral artery disease] cohort did not change peak walking time or MRI-based anatomic and perfusion endpoints,” reported Emerson C. Perin, MD, director of Clinical Research for Cardiovascular Medicine and medical director of the Stem Cell Center, both at the Texas Heart Institute, Houston.

Dr. Perin replied: “PAD is kind of the stepchild of cardiovascular medicine, it’s very poorly understood. And I think with the PACE trial, we’ve actually taken a huge step in understanding how we can treat these patients and how to study these patients.”

“Even though intermittent claudication or PAD starts with the flow limitation, what you wind up getting later down the road is not something that just relates to flow,” he elaborated. “We were able to study flow completely in this study – we owned it. What we weren’t able to study, and at the time we couldn’t, but now we can, is the metabolic, endothelial, and mitochondrial function. That is, what’s happening at the level of the muscle that is the missing link, together with the flow, that will give us these answers. So I think PACE [Patients With Intermittent Claudication Injected With ALDH Bright Cells] was very important to give us a greater understanding of where we can go now in PAD research.”

Trial details

Between 1 and 3 million people in the United States live with claudication, Dr. Perin noted when introducing the study. “It’s a very significant problem and a problem for which we really don’t have good solutions. We have one medicine [cilostazol], revascularization surgery, and stents that have recurrence – things that are less than perfect. There are also exercise programs, which not everyone has access to.”

The ALDH bright cells tested in PACE are collected from a patient’s bone marrow and express high levels of that enzyme. They are enriched for hematopoietic, endothelial progenitor, and multipotent mesenchymal colony-forming cells, and have shown ischemic repair capacity in preclinical models, with an increase in capillary density.

The investigators enrolled 82 patients with atherosclerotic peripheral arterial disease and symptom-limiting intermittent claudication of the legs. All had a pre-exercise ankle-brachial index of less than 0.9 or a pre-exercise toe-brachial index of less than 0.7, as well as stenosis greater than 50% or occlusion of infra-inguinal arteries by advanced imaging.

The patients were treated with 10 1-mL injections of ALDH bright cells or placebo into muscles of the posterior lower thigh and calf.

Results showed that after 6 months, peak treadmill walking time had improved by 2.2 minutes in the cell therapy group and 1.2 minutes in the placebo group, but the difference was not significant, Dr. Perin reported. The groups also were statistically indistinguishable overall with respect to changes in ankle-brachial index, walking impairment, and symptoms, and in MRI-assessed collateral count, peak hyperemic flow in the popliteal artery, and capillary perfusion.

However, among the subgroup of patients having a pre-exercise ankle-brachial index of 0.6 or less at baseline, collateral count increased by 2.4 in the cell therapy group, compared with 0.5 in the placebo group (P = .021).

In addition, among patients who had occluded femoral arteries at baseline (having more collateral vessels than peers with patent femoral arteries), the number of collaterals increased by 1.5 in the cell therapy group, compared with 0.3 in the placebo group (P = .047).

“This suggests an arteriogenic effect of cell therapy in patients with an occluded femoral artery substrate,” said Dr. Perin, who disclosed that he received a research grant from the National Heart, Lung, and Blood Institute.

NEW ORLEANS – Therapy with cells known to repair ischemic damage does not improve intermittent claudication of the legs in unselected patients, according to data from the randomized, phase II PACE trial reported at the American Heart Association scientific sessions. But some patients had evidence of new vessel formation.

“Administration of ALDH [aldehyde dehydrogenase] bright cells was feasible and safe, [but] administration at this dose and in this PAD [peripheral artery disease] cohort did not change peak walking time or MRI-based anatomic and perfusion endpoints,” reported Emerson C. Perin, MD, director of Clinical Research for Cardiovascular Medicine and medical director of the Stem Cell Center, both at the Texas Heart Institute, Houston.

Dr. Perin replied: “PAD is kind of the stepchild of cardiovascular medicine, it’s very poorly understood. And I think with the PACE trial, we’ve actually taken a huge step in understanding how we can treat these patients and how to study these patients.”

“Even though intermittent claudication or PAD starts with the flow limitation, what you wind up getting later down the road is not something that just relates to flow,” he elaborated. “We were able to study flow completely in this study – we owned it. What we weren’t able to study, and at the time we couldn’t, but now we can, is the metabolic, endothelial, and mitochondrial function. That is, what’s happening at the level of the muscle that is the missing link, together with the flow, that will give us these answers. So I think PACE [Patients With Intermittent Claudication Injected With ALDH Bright Cells] was very important to give us a greater understanding of where we can go now in PAD research.”

Trial details

Between 1 and 3 million people in the United States live with claudication, Dr. Perin noted when introducing the study. “It’s a very significant problem and a problem for which we really don’t have good solutions. We have one medicine [cilostazol], revascularization surgery, and stents that have recurrence – things that are less than perfect. There are also exercise programs, which not everyone has access to.”

The ALDH bright cells tested in PACE are collected from a patient’s bone marrow and express high levels of that enzyme. They are enriched for hematopoietic, endothelial progenitor, and multipotent mesenchymal colony-forming cells, and have shown ischemic repair capacity in preclinical models, with an increase in capillary density.

The investigators enrolled 82 patients with atherosclerotic peripheral arterial disease and symptom-limiting intermittent claudication of the legs. All had a pre-exercise ankle-brachial index of less than 0.9 or a pre-exercise toe-brachial index of less than 0.7, as well as stenosis greater than 50% or occlusion of infra-inguinal arteries by advanced imaging.

The patients were treated with 10 1-mL injections of ALDH bright cells or placebo into muscles of the posterior lower thigh and calf.

Results showed that after 6 months, peak treadmill walking time had improved by 2.2 minutes in the cell therapy group and 1.2 minutes in the placebo group, but the difference was not significant, Dr. Perin reported. The groups also were statistically indistinguishable overall with respect to changes in ankle-brachial index, walking impairment, and symptoms, and in MRI-assessed collateral count, peak hyperemic flow in the popliteal artery, and capillary perfusion.

However, among the subgroup of patients having a pre-exercise ankle-brachial index of 0.6 or less at baseline, collateral count increased by 2.4 in the cell therapy group, compared with 0.5 in the placebo group (P = .021).

In addition, among patients who had occluded femoral arteries at baseline (having more collateral vessels than peers with patent femoral arteries), the number of collaterals increased by 1.5 in the cell therapy group, compared with 0.3 in the placebo group (P = .047).

“This suggests an arteriogenic effect of cell therapy in patients with an occluded femoral artery substrate,” said Dr. Perin, who disclosed that he received a research grant from the National Heart, Lung, and Blood Institute.

To the Editor:
Down syndrome (DS) is associated with rare dermatological disorders, and the prevalence of some common dermatoses is greater in patients with DS. We report a case of milialike idiopathic calcinosis cutis (MICC) associated with syringomas in a patient with DS. We emphasize that MICC is one of the rare dermatoses associated with DS.

A 4-year-old girl with DS presented with a 4-mm, flesh-colored, regular-bordered, exophytic papular lesion on the left upper eyelid of 8 months' duration (Figure 1). It was clinically recognized as syringoma. On dermatologic examination of the patient, there also were 1- to 3-mm, round, whitish, painless, milialike papules on the dorsal surface of the hands and wrists (Figure 2). Some of these papules were surrounded by erythema. There was no sign of perforation. Her personal and family history were unremarkable.

Histopathologic examination of a biopsy from a  milialike lesion on the hand showed a hyperkeratotic epidermis. In the dermis there was a roundish calcific nodule surrounded by a fibrovascular rim. The patient's guardians refused a biopsy from the lesion on the eyelid.

Laboratory tests including serum vitamin D, thyroid and parathyroid hormone, calcium, phosphorus, and urinary calcium levels, as well as renal function tests, were within reference range. On the basis of these clinical and histopathological findings, the patient was diagnosed with MICC and palpebral syringoma.

Many dermatoses associated with DS have been reported including elastosis perforans serpiginosa, alopecia areata, and syringomas.^1-3 Sano et al4 first described MICC and syringomas in a patient with DS in 1978. Milialike idiopathic calcinosis cutis is characterized by asymptomatic, millimetric, firm, round, whitish papules that are sometimes surrounded by erythema. These papules may show perforation leading to transepidermal elimination of calcium, similar to the transdermal elimination of elastic fibrils in elastosis perforans serpiginosa. Although MICC usually is described in acral sites of children with DS, it also is reported in adults without DS and on other parts of the body.^5-7

The cause of MICC is unknown. One hypothesis of the development of MICC is an increase of the calcium content in the sweat leading to calcification of the acrosyringium.⁸ Milia are small keratin cysts that usually develop by occlusion of the hair follicle, sweat duct, or sebaceous duct. However, milia also can occur from occlusion of the eccrine ducts where syringomas originate.⁹ Therefore, syringomas can be seen in association with milia and calcium deposits.^5,9-11

We believe that MICC in DS may be more common than usually recognized, as the lesions often are asymptomatic. It is important to differentiate MICC from other dermatological diseases such as molluscum contagiosum, verruca plana, milia, and inclusion cysts. Histopathology and dermoscopy could aid in the accurate diagnosis of MICC.

To the Editor:
Down syndrome (DS) is associated with rare dermatological disorders, and the prevalence of some common dermatoses is greater in patients with DS. We report a case of milialike idiopathic calcinosis cutis (MICC) associated with syringomas in a patient with DS. We emphasize that MICC is one of the rare dermatoses associated with DS.

A 4-year-old girl with DS presented with a 4-mm, flesh-colored, regular-bordered, exophytic papular lesion on the left upper eyelid of 8 months' duration (Figure 1). It was clinically recognized as syringoma. On dermatologic examination of the patient, there also were 1- to 3-mm, round, whitish, painless, milialike papules on the dorsal surface of the hands and wrists (Figure 2). Some of these papules were surrounded by erythema. There was no sign of perforation. Her personal and family history were unremarkable.

Histopathologic examination of a biopsy from a  milialike lesion on the hand showed a hyperkeratotic epidermis. In the dermis there was a roundish calcific nodule surrounded by a fibrovascular rim. The patient's guardians refused a biopsy from the lesion on the eyelid.

Laboratory tests including serum vitamin D, thyroid and parathyroid hormone, calcium, phosphorus, and urinary calcium levels, as well as renal function tests, were within reference range. On the basis of these clinical and histopathological findings, the patient was diagnosed with MICC and palpebral syringoma.

Many dermatoses associated with DS have been reported including elastosis perforans serpiginosa, alopecia areata, and syringomas.^1-3 Sano et al4 first described MICC and syringomas in a patient with DS in 1978. Milialike idiopathic calcinosis cutis is characterized by asymptomatic, millimetric, firm, round, whitish papules that are sometimes surrounded by erythema. These papules may show perforation leading to transepidermal elimination of calcium, similar to the transdermal elimination of elastic fibrils in elastosis perforans serpiginosa. Although MICC usually is described in acral sites of children with DS, it also is reported in adults without DS and on other parts of the body.^5-7

The cause of MICC is unknown. One hypothesis of the development of MICC is an increase of the calcium content in the sweat leading to calcification of the acrosyringium.⁸ Milia are small keratin cysts that usually develop by occlusion of the hair follicle, sweat duct, or sebaceous duct. However, milia also can occur from occlusion of the eccrine ducts where syringomas originate.⁹ Therefore, syringomas can be seen in association with milia and calcium deposits.^5,9-11

We believe that MICC in DS may be more common than usually recognized, as the lesions often are asymptomatic. It is important to differentiate MICC from other dermatological diseases such as molluscum contagiosum, verruca plana, milia, and inclusion cysts. Histopathology and dermoscopy could aid in the accurate diagnosis of MICC.

To the Editor:
Down syndrome (DS) is associated with rare dermatological disorders, and the prevalence of some common dermatoses is greater in patients with DS. We report a case of milialike idiopathic calcinosis cutis (MICC) associated with syringomas in a patient with DS. We emphasize that MICC is one of the rare dermatoses associated with DS.

A 4-year-old girl with DS presented with a 4-mm, flesh-colored, regular-bordered, exophytic papular lesion on the left upper eyelid of 8 months' duration (Figure 1). It was clinically recognized as syringoma. On dermatologic examination of the patient, there also were 1- to 3-mm, round, whitish, painless, milialike papules on the dorsal surface of the hands and wrists (Figure 2). Some of these papules were surrounded by erythema. There was no sign of perforation. Her personal and family history were unremarkable.

Histopathologic examination of a biopsy from a  milialike lesion on the hand showed a hyperkeratotic epidermis. In the dermis there was a roundish calcific nodule surrounded by a fibrovascular rim. The patient's guardians refused a biopsy from the lesion on the eyelid.

Laboratory tests including serum vitamin D, thyroid and parathyroid hormone, calcium, phosphorus, and urinary calcium levels, as well as renal function tests, were within reference range. On the basis of these clinical and histopathological findings, the patient was diagnosed with MICC and palpebral syringoma.

Many dermatoses associated with DS have been reported including elastosis perforans serpiginosa, alopecia areata, and syringomas.^1-3 Sano et al4 first described MICC and syringomas in a patient with DS in 1978. Milialike idiopathic calcinosis cutis is characterized by asymptomatic, millimetric, firm, round, whitish papules that are sometimes surrounded by erythema. These papules may show perforation leading to transepidermal elimination of calcium, similar to the transdermal elimination of elastic fibrils in elastosis perforans serpiginosa. Although MICC usually is described in acral sites of children with DS, it also is reported in adults without DS and on other parts of the body.^5-7

The cause of MICC is unknown. One hypothesis of the development of MICC is an increase of the calcium content in the sweat leading to calcification of the acrosyringium.⁸ Milia are small keratin cysts that usually develop by occlusion of the hair follicle, sweat duct, or sebaceous duct. However, milia also can occur from occlusion of the eccrine ducts where syringomas originate.⁹ Therefore, syringomas can be seen in association with milia and calcium deposits.^5,9-11

We believe that MICC in DS may be more common than usually recognized, as the lesions often are asymptomatic. It is important to differentiate MICC from other dermatological diseases such as molluscum contagiosum, verruca plana, milia, and inclusion cysts. Histopathology and dermoscopy could aid in the accurate diagnosis of MICC.

WASHINGTON – Mesh fixation technique is not a factor in persistent pain after transabdominal preperitoneal (TAPP) groin hernia surgery, a study showed.

“Persistent pain is a well-known phenomenon after groin hernia surgery,” said Jakob Burcharth, MD, of University Hospital of Sjaelland Koge (Denmark). “The way that we fixate the mesh in laparoscopic surgery has been hypothesized to have an [impact] on the risk of persistent pain.”

In a study presented by Dr. Burcharth and his associates at the American College of Surgeons Clinical Congress, a total of 1,421 patients were examined. Each patient completed a validated pain questionnaire through the Danish Hernia Database from 2009 to 2012. The patients were divided into two groups: Group 1 had spray fibrin sealant (34%) for mesh fixation, and group 2 had tacks (66%). The results showed no difference between the groups in terms of pain in getting up from a chair, sitting or standing for more than 30 minutes, walking stairs, driving a car, or exercising, or in the need for postoperative analgesics or postoperative sick leave (all P greater than .20).

©monkeybusinessimages/Thinkstock

[email protected]

WASHINGTON – Mesh fixation technique is not a factor in persistent pain after transabdominal preperitoneal (TAPP) groin hernia surgery, a study showed.

“Persistent pain is a well-known phenomenon after groin hernia surgery,” said Jakob Burcharth, MD, of University Hospital of Sjaelland Koge (Denmark). “The way that we fixate the mesh in laparoscopic surgery has been hypothesized to have an [impact] on the risk of persistent pain.”

In a study presented by Dr. Burcharth and his associates at the American College of Surgeons Clinical Congress, a total of 1,421 patients were examined. Each patient completed a validated pain questionnaire through the Danish Hernia Database from 2009 to 2012. The patients were divided into two groups: Group 1 had spray fibrin sealant (34%) for mesh fixation, and group 2 had tacks (66%). The results showed no difference between the groups in terms of pain in getting up from a chair, sitting or standing for more than 30 minutes, walking stairs, driving a car, or exercising, or in the need for postoperative analgesics or postoperative sick leave (all P greater than .20).

©monkeybusinessimages/Thinkstock

[email protected]

WASHINGTON – Mesh fixation technique is not a factor in persistent pain after transabdominal preperitoneal (TAPP) groin hernia surgery, a study showed.

“Persistent pain is a well-known phenomenon after groin hernia surgery,” said Jakob Burcharth, MD, of University Hospital of Sjaelland Koge (Denmark). “The way that we fixate the mesh in laparoscopic surgery has been hypothesized to have an [impact] on the risk of persistent pain.”

In a study presented by Dr. Burcharth and his associates at the American College of Surgeons Clinical Congress, a total of 1,421 patients were examined. Each patient completed a validated pain questionnaire through the Danish Hernia Database from 2009 to 2012. The patients were divided into two groups: Group 1 had spray fibrin sealant (34%) for mesh fixation, and group 2 had tacks (66%). The results showed no difference between the groups in terms of pain in getting up from a chair, sitting or standing for more than 30 minutes, walking stairs, driving a car, or exercising, or in the need for postoperative analgesics or postoperative sick leave (all P greater than .20).

©monkeybusinessimages/Thinkstock

[email protected]